USX: Introducing PharmaZen Limited

Pharmazen Limited Issuer Profile

PharmaZen Ltd (PAZ), trading as Waitaki Biosciences, is a a biotechnological company based in Christchurch, New Zealand.

It is principally involved in the development, manufacture and business to business marketing of specialised nutritional ingredients for human and companion animal dietary supplement products. Exported product typically generates in excess of 90% of revenune annually. 

PharmaZen offers its international customer base a portfolio of branded ingredients with specific functionality in bone and joint health, anti-inflammation, immune support, digestive health and anti-oxidant capability. 

The company is chaired by Maxwell Shepherd, with Kenneth Fergus, Wayne Burt and Peter Dobbs in directorship roles.

Comments from our readers

No comments yet

Add your comment:

Your name:
Your email:	Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Anti-spam verification:

Type the text you see in the image into the field below. You are asked to do this in order to verify that this enquiry is not being performed by an automated process.

Related News:

HGH Ltd Results for the 6 months ended 1 February 2026
March 27th Morning Report
CDC investor presentation and guidance update
PFI - Potential Bond Offer by PFI
MCY - Mercury Green Bond offer - interest rate set
March 25th Morning Report
AFT - Chief Financial Officer update
KMD Brands: Response to Stokehouse transaction concept
March 24th Morning Report
MCY - Mercury launches retail Green Bond offer